These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31924369)

  • 1. Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Wang F; Qin J; Xie F; Wu Q; Lu H
    Lung Cancer; 2020 Feb; 140():118-120. PubMed ID: 31924369
    [No Abstract]   [Full Text] [Related]  

  • 2. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J; Gu D; Lu H; Liu S; Kong J
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract]   [Full Text] [Related]  

  • 3. A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib.
    Lin H; Ren G; Liang X
    J Thorac Oncol; 2018 Nov; 13(11):e234-e236. PubMed ID: 30368418
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X; Wang W; Zou B; Li Y; Yang X; Liu N; Ma Q; Zhang X; Wang Y; Li D
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Novel EML4-ALK, BCL11A-ALK Double-Fusion Variant in Lung Adenocarcinoma Using Next-Generation Sequencing and Response to Crizotinib.
    Qin BD; Jiao XD; Liu K; Wu Y; Zang YS
    J Thorac Oncol; 2019 Jun; 14(6):e115-e117. PubMed ID: 31122560
    [No Abstract]   [Full Text] [Related]  

  • 8. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
    Fei X; Zhu L; Zhou H; Qi C; Wang C
    J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
    [No Abstract]   [Full Text] [Related]  

  • 9. Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.
    Chen X; Zhao G; Zhong P; Zhang M; Chen R; Zhang D
    Clin Lung Cancer; 2020 Nov; 21(6):e564-e566. PubMed ID: 32576444
    [No Abstract]   [Full Text] [Related]  

  • 10. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

  • 11. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of crizotinib-associated renal cysts].
    Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
    Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
    Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Zhang Y; Yu M; Yuan M; Chen R; Huang MJ
    Clin Lung Cancer; 2020 Mar; 21(2):e78-e83. PubMed ID: 31722815
    [No Abstract]   [Full Text] [Related]  

  • 15. EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.
    Batra U; Sharma M; Amrith BP; Mehta A; Jain P
    Clin Lung Cancer; 2020 Nov; 21(6):e597-e600. PubMed ID: 32620470
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.
    Hicks JK; Boyle T; Albacker LA; Madison R; Frampton G; Creelan BC
    J Thorac Oncol; 2018 Aug; 13(8):e148-e150. PubMed ID: 30049378
    [No Abstract]   [Full Text] [Related]  

  • 17. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
    Song P; Zhang J; Shang C; Zhang L
    Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma.
    Wang Q; Yang X; He Y; Ma Q; Lin L; Fu P; Xiao H
    J Mol Diagn; 2015 Sep; 17(5):515-20. PubMed ID: 26142544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.